Quanterix Co. (NASDAQ:QTRX) Stock Holdings Lessened by Platinum Investment Management Ltd.

Platinum Investment Management Ltd. reduced its position in shares of Quanterix Co. (NASDAQ:QTRX) by 6.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 260,181 shares of the company’s stock after selling 17,455 shares during the quarter. Platinum Investment Management Ltd. owned 0.68% of Quanterix worth $2,766,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. Peapack Gladstone Financial Corp bought a new stake in Quanterix during the third quarter valued at about $131,000. Intech Investment Management LLC acquired a new position in Quanterix in the third quarter worth about $170,000. Levin Capital Strategies L.P. acquired a new position in Quanterix in the fourth quarter worth about $159,000. Tallon Kerry Patrick acquired a new position in Quanterix in the fourth quarter worth about $169,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Quanterix during the third quarter worth approximately $258,000. 86.48% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group decreased their price target on shares of Quanterix from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday.

Quanterix Stock Performance

Shares of QTRX opened at $7.15 on Wednesday. Quanterix Co. has a 52 week low of $6.30 and a 52 week high of $27.37. The firm has a market cap of $275.45 million, a P/E ratio of -6.75 and a beta of 1.34. The firm’s 50-day simple moving average is $8.41 and its 200 day simple moving average is $10.93.

Quanterix (NASDAQ:QTRX) last announced its earnings results on Monday, March 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. The business had revenue of $35.16 million for the quarter, compared to analyst estimates of $34.93 million. As a group, equities analysts forecast that Quanterix Co. will post -0.98 earnings per share for the current year.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.